title: [The role of Stratus OCT in anti-VEGF therapy. Qualitative and quantitative assessment of neovascular AMD].
abstract: BACKGROUND
  The evaluation of OCT3 during anti-VEGF therapy.
  
  
  METHODS
  A total of 29 patients with choroidal neovascularization secondary to AMD received 3 intravitreal injections of ranibizumab. OCT examination and visual acuity testing (ETDRS) were performed before therapy onset, after 1 week and after 1, 2 and 3 months.
  
  
  RESULTS
  The central retinal thickness (CRT) was assessed correctly by OCT in 128 out of 145 measurements. There was a distinct (84%) but not significant correlation between decrease in central retinal thickness and increase in visual acuity. Incorrect retinal layer segmentation and inadequate CRT measurements were a significant technical limitation.
  
  
  CONCLUSIONS
  During anti-VEGF therapy, OCT allows documentation and quantification of morphologic retinal changes and in most cases also for an estimation of functional improvement.
authors.affiliation: Universitätsklinik für Augenheilkunde und Optometrie, Medizinische Universität Wien, Währinger Gürtel 18-20, 1090, Wien, Osterreich.
authors.forename: M
authors.initials: M
authors.lastname: Bolz
authors.forename: M
authors.initials: M
authors.lastname: Ritter
authors.forename: K
authors.initials: K
authors.lastname: Polak
authors.forename: C
authors.initials: C
authors.lastname: Ahlers
authors.forename: C
authors.initials: C
authors.lastname: Hirn
authors.forename: C
authors.initials: C
authors.lastname: Prünte
authors.forename: I
authors.initials: I
authors.lastname: Golbaz
authors.forename: T
authors.initials: T
authors.lastname: Benesch
authors.forename: U
authors.initials: U
authors.lastname: Schmidt-Erfurth
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D016510:Corneal Neovascularization / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D007090:Image Interpretation, Computer-Assisted / Q000379:methods*; D008268:Macular Degeneration / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D008297:Male; D011379:Prognosis; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A